Tziastoudi M, Pissas G, Golfinopoulos S, Filippidis G, Poulianiti C, Tsironi E
Int J Mol Sci. 2024; 25(20).
PMID: 39456691
PMC: 11508130.
DOI: 10.3390/ijms252010906.
Li Y, Hirayasu K, Hasegawa G, Tomita Y, Hashikawa Y, Hiwa R
Front Immunol. 2024; 15:1435236.
PMID: 39376567
PMC: 11456740.
DOI: 10.3389/fimmu.2024.1435236.
Johnson T, Mukhopadhyay S, Buzza M, Brooks J, Sarkar R, Antalis T
Thromb Res. 2024; 243:109149.
PMID: 39317013
PMC: 11486561.
DOI: 10.1016/j.thromres.2024.109149.
Zabihi M, Akhoondian M, Tohidian M, Karkhah S, Ghorbani Vajargah P, Mazhari S
Ann Med Surg (Lond). 2024; 86(9):5162-5169.
PMID: 39239032
PMC: 11374194.
DOI: 10.1097/MS9.0000000000002240.
Piao Y, Kim H, Kim H, Shen J, Moon W
BMC Cancer. 2024; 24(1):792.
PMID: 38956496
PMC: 11221169.
DOI: 10.1186/s12885-024-12473-6.
Estetrol/GPER/SERPINB2 transduction signaling inhibits the motility of triple-negative breast cancer cells.
Cirillo F, Spinelli A, Talia M, Scordamaglia D, Santolla M, Grande F
J Transl Med. 2024; 22(1):450.
PMID: 38741146
PMC: 11089683.
DOI: 10.1186/s12967-024-05269-6.
circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma.
Xu L, Wang P, Li L, Li L, Huang Y, Zhang Y
Mol Cancer. 2023; 22(1):174.
PMID: 37884951
PMC: 10601121.
DOI: 10.1186/s12943-023-01882-z.
ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway.
Bharadwaj A, McLean M, Dahn M, Cahill H, Wasson M, Arun R
Mol Oncol. 2023; 18(1):91-112.
PMID: 37753740
PMC: 10766202.
DOI: 10.1002/1878-0261.13528.
Spider venom-derived peptide JZTX-14 prevents migration and invasion of breast cancer cells inhibition of sodium channels.
Wu W, Yin Y, Feng P, Chen G, Pan L, Gu P
Front Pharmacol. 2023; 14:1067665.
PMID: 37033662
PMC: 10076671.
DOI: 10.3389/fphar.2023.1067665.
Posttranscriptional Regulation of the Plasminogen Activation System by Non-Coding RNA in Cancer.
Alfieri M, Meo L, Ragno P
Int J Mol Sci. 2023; 24(2).
PMID: 36674481
PMC: 9860977.
DOI: 10.3390/ijms24020962.
, an Early Responsive Gene to Epigallocatechin Gallate, Inhibits Migration and Promotes Apoptosis in Esophageal Cancer Cells.
Chen Z, Wei Y, Zheng Y, Zhu H, Teng Q, Lin X
Cells. 2022; 11(23).
PMID: 36497110
PMC: 9738437.
DOI: 10.3390/cells11233852.
The role of plasminogen activator inhibitor-2 in pneumococcal meningitis.
Teske N, Engelen-Lee J, Dyckhoff-Shen S, Pfister H, Klein M, van de Beek D
Acta Neuropathol Commun. 2022; 10(1):155.
PMID: 36309755
PMC: 9617400.
DOI: 10.1186/s40478-022-01461-1.
The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer.
Nelczyk A, Ma L, Das Gupta A, Vidana Gamage H, McHenry M, Henn M
Biochim Biophys Acta Mol Basis Dis. 2022; 1868(11):166515.
PMID: 35932893
PMC: 9983295.
DOI: 10.1016/j.bbadis.2022.166515.
Transcriptome analysis of SerpinB2-deficient breast tumors provides insight into deciphering SerpinB2-mediated roles in breast cancer progression.
Piao Y, Kim H, Han W, Moon W
BMC Genomics. 2022; 23(1):479.
PMID: 35768767
PMC: 9241327.
DOI: 10.1186/s12864-022-08704-4.
Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review).
Zuzcak M, Trnka J
Int J Oncol. 2022; 61(2).
PMID: 35730611
PMC: 9256076.
DOI: 10.3892/ijo.2022.5383.
A tEMTing target? Clinical and experimental evidence for epithelial-mesenchymal transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic review).
Genenger B, Perry J, Ashford B, Ranson M
Discov Oncol. 2022; 13(1):42.
PMID: 35666359
PMC: 9170863.
DOI: 10.1007/s12672-022-00510-4.
Structure-Activity Relationship of Benzofuran Derivatives with Potential Anticancer Activity.
Farhat J, Alzyoud L, Alwahsh M, Al-Omari B
Cancers (Basel). 2022; 14(9).
PMID: 35565325
PMC: 9099631.
DOI: 10.3390/cancers14092196.
Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.
El Salamouni N, Buckley B, Ranson M, Kelso M, Yu H
Biophys Rev. 2022; 14(1):277-301.
PMID: 35340592
PMC: 8921380.
DOI: 10.1007/s12551-021-00921-7.
The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.
Kumar A, Buckley B, Ranson M
Biomolecules. 2022; 12(2).
PMID: 35204653
PMC: 8961517.
DOI: 10.3390/biom12020152.
The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis.
Anwar Ismail A, Shaker B, Bajou K
Int J Mol Sci. 2022; 23(1).
PMID: 35008762
PMC: 8745544.
DOI: 10.3390/ijms23010337.